Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 17/20 | 0.72 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.67 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710134 | 1.00 | SMYD3 (0.72) | SMYD3MAPK11MAPK14CHRNA7KDM4E | |
| SCHEMBL21489951 | 0.91 | SMYD3 (0.72) | SMYD3MAPK11MAPK14CHRNA7 | |
| SCHEMBL19710019 | 0.91 | SMYD3 (0.72) | SMYD3MAPK11MAPK14CHRNA7 | |
| SCHEMBL6204351 | 0.86 | MAPK14 (0.70) | SMYD3MAPK11MAPK14CHRNA7KDM4E | |
| SCHEMBL6204355 | 0.86 | MAPK14 (0.70) | SMYD3MAPK11MAPK14CHRNA7KDM4E | |
| SCHEMBL24950457 | 0.86 | SMYD3 (0.67) | SMYD3MAPK11MAPK14CHRNA7KDM4E | |
| SCHEMBL17443589 | 0.84 | SMYD3 (0.65) | SMYD3MAPK11MAPK14CHRNA7KDM4E | |
| SCHEMBL21489831 | 0.84 | SMYD3 (1.00) | SMYD3MAPK11MAPK14 | |
| SCHEMBL19710171 | 0.84 | SMYD3 (1.00) | SMYD3MAPK11MAPK14 | |
| SCHEMBL4592419 | 0.83 | SMYD3 (0.77) | SMYD3MAPK11MAPK14CHRNA7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | claimed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | SMYD3 1/4885MAPK11 3658/4885MAPK14 3692/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | SMYD3 2/4885MAPK11 3459/4885MAPK14 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.